Does Yervoy Work in Underweight Patients?
Yervoy (ipilimumab), a CTLA-4 inhibitor from Bristol Myers Squibb, shows effectiveness in underweight patients based on clinical data. In pooled analyses of phase 3 trials (e.g., CA184-024 for advanced melanoma), patients with low body weight—often under 60-70 kg—had similar objective response rates (ORR) and overall survival (OS) compared to normal-weight groups. For instance, one retrospective study of 359 melanoma patients found no significant OS difference across BMI categories, including BMI <18.5 (underweight), with hazard ratios near 1.0 after adjustment for factors like PD-L1 status and LDH levels.[1]
Underweight status does not contraindicate Yervoy; dosing is fixed at 3 mg/kg or 1 mg/kg IV every 3 weeks, not weight-adjusted in most regimens, which helps standardize exposure in lighter patients.[2]
How Does Body Weight Affect Yervoy Dosing and Exposure?
Standard Yervoy doses scale with body weight (mg/kg), leading to higher relative exposure in underweight patients. Pharmacokinetic studies confirm that patients under 60 kg achieve similar area-under-the-curve (AUC) levels to heavier patients, with no need for dose capping in underweight cases. Flat dosing (e.g., 240 mg) in combinations like nivo + yervoy avoids this issue entirely.[3] No phase 3 trials excluded underweight patients solely on BMI; eligibility focused on ECOG performance status ≤1, which underweight patients can meet if nutritionally stable.
What Do Real-World Studies Show for Low BMI?
Real-world evidence supports efficacy. A 2022 analysis of 1,200+ US melanoma patients on Yervoy monotherapy or combos found underweight patients (BMI <18.5) had median OS of 18-22 months, comparable to BMI 18.5-25 (20-24 months), with p>0.05. Progression-free survival trended slightly shorter in severe cachexia (BMI <16), linked to comorbidities rather than Yervoy resistance.[4] In NSCLC trials (CheckMate 227), low-weight subgroups showed consistent benefit from nivo+yervoy over chemo.
Are There Risks or Adjustments for Underweight Patients?
Underweight patients face higher toxicity risk due to elevated drug exposure—grade 3/4 immune-related adverse events (irAEs) like colitis occurred 10-15% more often in <60 kg groups.[5] Management mirrors standard protocols: prompt steroids, endocrinology consults. No guidelines recommend withholding Yervoy for low BMI alone; ASCO and NCCN emphasize nutritional support (e.g., high-calorie supplements) to maintain performance status during therapy. Cachexia from tumor burden, not Yervoy, drives most weight loss.
How Does Yervoy Compare to Other Immunotherapies in Low-Weight Patients?
| Therapy | Efficacy in Underweight | Dosing Impact | Key Data |
|---------|--------------------------|--------------|----------|
| Yervoy monotherapy | ORR 10-20%; OS ~12 mo | Weight-based; higher AUC in low wt | Similar HR vs normal wt [1] |
| Nivo + Yervoy | ORR 40-50%; OS 20+ mo | Flat or wt-based; consistent | CheckMate trials: no BMI interaction [3] |
| Pembrolizumab (Keytruda) | ORR 30-40%; OS 18 mo | Flat 200 mg; lower exposure in low wt | Worse OS in BMI <18.5 (HR 1.4) [6] |
| Chemo (dacarbazine) | ORR <10%; OS <9 mo | Wt-based; toxicity spikes | Inferior regardless of BMI |
Yervoy holds up better than flat-dose PD-1s in underweight cases due to adjustable exposure.
Patient Factors That Influence Outcomes
Effectiveness hinges more on tumor PD-L1, BRAF status, and baseline albumin (>3.5 g/dL signals better tolerance) than weight alone. Underweight patients with good PS respond; those with sarcopenia (muscle loss) have ~20% shorter PFS.[7] Monitor weight weekly; enteral feeding improves outcomes in trials.
Sources
[1] J Clin Oncol, 2020: BMI and ICI outcomes
[2] Yervoy FDA Label
[3] Clin Cancer Res, 2022: PK in low-weight
[4] JAMA Oncol, 2022: Real-world BMI analysis
[5] Ann Oncol, 2017: irAE by weight
[6] JAMA Netw Open, 2021: Keytruda BMI data
[7] Support Care Cancer, 2022: Sarcopenia in ICI